258 related articles for article (PubMed ID: 7917927)
1. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I
J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718
[TBL] [Abstract][Full Text] [Related]
3. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
4. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.
Seymour MT; Patel N; Johnston A; Joel SP; Slevin ML
Br J Cancer; 1994 Oct; 70(4):724-8. PubMed ID: 7917928
[TBL] [Abstract][Full Text] [Related]
8. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
Bernhard H; Jäger-Arand E; Bernhard G; Heike M; Klein O; Riemann JF; Meyer zum Büschenfelde KH; Dippold W; Knuth A
Br J Cancer; 1995 Jan; 71(1):102-5. PubMed ID: 7819023
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Rigg A; Cunningham D; Gore M; Hill M; O'Brien M; Nicolson M; Chang J; Watson M; Norman A; Hill A; Oates J; Moore H; Ross P
Br J Cancer; 1997; 75(1):101-5. PubMed ID: 9000605
[TBL] [Abstract][Full Text] [Related]
14. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Yee LK; Allegra CJ; Steinberg SM; Grem JL
J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
[TBL] [Abstract][Full Text] [Related]
15. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
16. Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
Aschele C; Guglielmi A; Frassineti GL; Milandri C; Amadori D; Labianca R; Vinci M; Tixi L; Caroti C; Ciferri E; Verdi E; Rosso R; Sobrero A
Br J Cancer; 1998; 77(2):341-6. PubMed ID: 9461008
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
18. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Ismail AS; Quinn MG; Wright MA; Ernst A; Kao V; Grogan L; Parr A; Grollman F; Kirsch IR; Grem JL
Oncol Rep; 2005 Jun; 13(6):1145-52. PubMed ID: 15870935
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas.
Scheithauer W; Pfeffel F; Kornek G; Marczell A; Wiltschke C; Funovics J
Cancer; 1992 Oct; 70(7):1864-6. PubMed ID: 1525760
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
